Opendata, web and dolomites

REPO-TRIAL SIGNED

An in silico-based approach to improve the efficacy and precision of drug REPurpOsing TRIALs for a mechanism-based patient cohort with predominant cerebro-cardiovascular phenotypes

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 REPO-TRIAL project word cloud

Explore the words cloud of the REPO-TRIAL project. It provides you a very rough idea of what is the project "REPO-TRIAL" about.

cardiovascular    translation    meta    identifies    stratified    benefit    confirmatory    scientifically    systematic    vagueness    apparent    diagnostics    choose    phenotype    virtual    size    chosen    reviews    classes    discovered    describe    trial    reduce    gov    org    efficacy    putatively    drugs    disease    experimentation    clinical    diseases    mechanistically    computer    disturbance    repurposing    innovate    validate    applicable    industrial    biomedical    pendant    definitions    prcts    animal    preclinical    generates    equilibria    time    simulation    panel    platform    self    drug    biomolecular    validation    phenotypes    biomarker    risks    patients    our    cohort    models    de    novo    facilitated    clinicaltrials    randomised    regulation    unrealistic    competitiveness    reduces    of    cerebro    reducing    repositionings    trials    silico    mechanistic    organ    medicine    exclusive    generally    innovative    symptom    enhances    frame    patient    precision    rapid   

Project "REPO-TRIAL" data sheet

The following table provides information about the project.

Coordinator
UNIVERSITEIT MAASTRICHT 

Organization address
address: Minderbroedersberg 4-6
city: MAASTRICHT
postcode: 6200 MD
website: http://www.maastrichtuniversity.nl

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Netherlands [NL]
 Project website https://repo-trial.eu/
 Total cost 5˙536˙775 €
 EC max contribution 5˙536˙772 € (100%)
 Programme 1. H2020-EU.3.1.5. (Methods and data)
 Code Call H2020-SC1-2017-CNECT-2
 Funding Scheme RIA
 Starting year 2018
 Duration (year-month-day) from 2018-02-01   to  2023-01-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    UNIVERSITEIT MAASTRICHT NL (MAASTRICHT) coordinator 1˙270˙089.00
2    UNIVERSITY OF NEWCASTLE UPON TYNE UK (NEWCASTLE UPON TYNE) participant 844˙728.00
3    TECHNISCHE UNIVERSITAET MUENCHEN DE (MUENCHEN) participant 742˙045.00
4    UNIVERSITAETSKLINIKUM ESSEN DE (ESSEN) participant 597˙565.00
5    MEDIZINISCHE HOCHSCHULE HANNOVER DE (HANNOVER) participant 550˙722.00
6    UNIVERSITAIR MEDISCH CENTRUM UTRECHT NL (UTRECHT) participant 550˙722.00
7    Concentris Research Management GmbH DE (Fürstenfeldbruck) participant 355˙026.00
8    SOMALOGIC LIMITED UK (CHOBHAM) participant 342˙964.00
9    BIOCRATES LIFE SCIENCES AG AT (INNSBRUCK) participant 157˙789.00
10    MUCKE HERMANN AT (WIEN) participant 125˙122.00
11    SYDDANSK UNIVERSITET DK (ODENSE M) participant 0.00

Map

 Project objective

Our programme will develop an innovative in-silico based approach to improve the efficacy and precision of drug repurposing trials. We have chosen drug repurposing as it has the shortest time for clinical validation and translation. Validation of all putatively de novo discovered drug repositionings within the time-frame of this programme would be unrealistic. To improve efficacy and precision, and to adopt our computer simulation parameters and models, we choose a systems medicine based in-silico approach that identifies mechanistically related disease phenotypes and, as a result, a virtual patient cohort. We then validate this in-silico drug repurposing via high precision clinical trials in patients with cerebro-cardiovascular phenotypes stratified using an exclusive mechanistic biomarker panel. We thus innovate two biomedical product classes, drugs and diagnostics. With this we will establish generally applicable in silico trials for other mechanistically related or defined disease phenotypes, for which size, duration, and risks will be reduced and precision increased. This generates rapid patient benefit, reduces drug development costs as well as risks, and enhances industrial competitiveness. Scientifically, we will contribute to reducing the uncertainty and vagueness of many of our current disease definitions that describe a symptom or apparent phenotype in an organ rather than defining diseases mechanistically as disturbance of self-regulation equilibria of biomolecular processes. Finally, we will reduce animal experimentation and animal numbers in general by applying a preclinical randomised confirmatory trial (pRCTs) concept and preclinical systematic reviews and meta-analyses facilitated by our open access pre-clinicaltrials.org platform, a pendant to clinicaltrials.gov.

 Deliverables

List of deliverables.
Project brochure and professional templates Websites, patent fillings, videos etc. 2019-11-06 13:06:26
Software for detection of pathway co-enrichment for extracting of patient(group)-specific pathways also enriched in target sites of effective drugs Other 2019-11-06 13:06:20
Communication and dissemination plan Websites, patent fillings, videos etc. 2019-11-06 13:06:11
Diseasome 2.0 network Other 2019-11-06 13:06:12

Take a look to the deliverables list in detail:  detailed list of REPO-TRIAL deliverables.

 Publications

year authors and title journal last update
List of publications.
2019 Mahmoud H. Elbatreek, Mayra P. Pachado, Antonio Cuadrado, Karin Jandeleit-Dahm, Harald H.H.W. Schmidt
Reactive Oxygen Comes of Age: Mechanism-Based Therapy of Diabetic End-Organ Damage
published pages: 312-327, ISSN: 1043-2760, DOI: 10.1016/j.tem.2019.02.006
Trends in Endocrinology & Metabolism 30/5 2019-09-26
2019 Ana I. Casas, Pamela W.M. Kleikers, Eva Geuss, Friederike Langhauser, Thure Adler, Dirk H. Busch, Valerie Gailus-Durner, Martin Hrabê de Angelis, Javier Egea, Manuela G. Lopez, Christoph Kleinschnitz, Harald H.H.W. Schmidt
Calcium-dependent blood-brain barrier breakdown by NOX5 limits postreperfusion benefit in stroke
published pages: 1772-1778, ISSN: 0021-9738, DOI: 10.1172/jci124283
Journal of Clinical Investigation 129/4 2019-09-26
2019 Ana I. Casas, Ahmed A. Hassan, Simon J. Larsen, Vanessa Gomez-Rangel, Mahmoud Elbatreek, Pamela W. M. Kleikers, Emre Guney, Javier Egea, Manuela G. López, Jan Baumbach, Harald H. H. W. Schmidt
From single drug targets to synergistic network pharmacology in ischemic stroke
published pages: 7129-7136, ISSN: 0027-8424, DOI: 10.1073/pnas.1820799116
Proceedings of the National Academy of Sciences 116/14 2019-09-26
2018 Joaquim Aguirre-Plans, Janet Piñero, Jörg Menche, Ferran Sanz, Laura Furlong, Harald Schmidt, Baldo Oliva, Emre Guney
Proximal Pathway Enrichment Analysis for Targeting Comorbid Diseases via Network Endopharmacology
published pages: 61, ISSN: 1424-8247, DOI: 10.3390/ph11030061
Pharmaceuticals 11/3 2019-09-26
2018 Simon J Larsen, Richard Röttger, Harald H H W Schmidt, Jan Baumbach
E. coli gene regulatory networks are inconsistent with gene expression data
published pages: 85-92, ISSN: 0305-1048, DOI: 10.1093/nar/gky1176
Nucleic Acids Research 47/1 2019-09-26

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "REPO-TRIAL" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "REPO-TRIAL" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.5.)

EUCANCan (2019)

EUCANCan: a federated network of aligned and interoperable infrastructures for the homogeneous analysis, management and sharing of genomic oncology data for Personalized Medicine.

Read More  

iReceptor Plus (2019)

ARCHITECTURE AND TOOLS FOR THE QUERY OF ANTIBODY AND T-CELL RECEPTOR SEQUENCING DATA REPOSITORIES FOR ENABLING IMPROVED PERSONALIZED MEDICINE AND IMMUNOTHERAPY

Read More  

CINECA (2019)

Common Infrastructure for National Cohorts in Europe, Canada, and Africa

Read More